TriangleHEALTH PROFESSIONAL · SOURCE READING
Subglottis
Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Stage III Laryngeal Cancer
Treatment options for stage III cancer of the subglottis include:
Laryngectomy plus isolated thyroidectomy and tracheoesophageal node dissection usually followed by PORT.[10]
Source links and citations
Treatment by radiation therapy alone is indicated for patients who are not candidates for surgery. Patients should be closely followed, and surgical salvage should be planned for recurrences that are local or in the neck.
Definitive radiation therapy alone with altered fractionation in patients who are not candidates for concurrent chemotherapy and surgery (total laryngectomy) for salvage of radiation failures.[6,7]
Source links and citations
Induction chemotherapy followed by concomitant chemotherapy and radiation. Laryngectomy is reserved for patients with less than a 50% response to chemotherapy or who have persistent disease after radiation.[6]
Source links and citations
Clinical trials exploring novel targeted therapy, immunotherapy, novel chemotherapy, radiosensitizers, or particle-beam radiation therapy.[9]
Source links and citations
For more information, see the Treatment Option Overview for Laryngeal Cancer section.
Source links and citations
Role of Neck Dissection in the Post-Radiation Therapy Setting
A prospective randomized trial included 564 patients with head and neck cancer and N2 or N3 disease. Patients were assigned to undergo planned neck dissection or surveillance with positron emission tomography–computed tomography (PET-CT). With a median follow-up of 36 months, PET-CT resulted in fewer neck dissections compared with the surgical arm (54 vs. 221), with a 2-year survival rate of 84.9% versus 81.5%, respectively. The hazard ratio (HR)death slightly favored PET-CT–guided surveillance and indicated noninferiority (upper boundary, 95% confidence interval for HR, <1.50; P = .004).[11][Level of evidence A1]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice